{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T09:30:24Z","timestamp":1781170224104,"version":"3.54.1"},"reference-count":105,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007397","name":"Charles University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007397","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100023503","name":"Department of Psychiatry","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100023503","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019214","name":"l\u00e9ka\u0159sk\u00e1 fakulta Univerzity Karlovy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019214","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100016366","name":"General University Hospital in Prague","doi-asserted-by":"publisher","award":["MH CZ \\u2013 DRO VFN64165"],"award-info":[{"award-number":["MH CZ \\u2013 DRO VFN64165"]}],"id":[{"id":"10.13039\/501100016366","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Frontiers in Neuroendocrinology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.yfrne.2025.101217","type":"journal-article","created":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T00:16:07Z","timestamp":1759536967000},"page":"101217","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Semaglutide and the pathogenesis of progressive neurodegenerative disease: the central role of mitochondria"],"prefix":"10.1016","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8146-0740","authenticated-orcid":false,"given":"George B.","family":"Stefano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"B\u00fcttiker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Weissenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiri","family":"Raboch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Anders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yfrne.2025.101217_b0005","article-title":"2025 Alzheimer\u2019s disease facts and figures","author":"Alzheimer\u2019s Association","year":"2025","journal-title":"Alzheimer\u2019s & Dementia. Advance Online Publication."},{"key":"10.1016\/j.yfrne.2025.101217_b0010","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/35042567","article-title":"Repeated, recent and diverse transfers of a mitochondrial gene to the nucleus in flowering plants","volume":"408","author":"Adams","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.yfrne.2025.101217_b0015","doi-asserted-by":"crossref","first-page":"9905","DOI":"10.1073\/pnas.042694899","article-title":"Punctuated evolution of mitochondrial gene content: High and variable rates of mitochondrial gene loss and transfer to the nucleus during angiosperm evolution","volume":"99","author":"Adams","year":"2002","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.yfrne.2025.101217_b0020","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.neuroscience.2015.05.023","article-title":"Glucagon-like peptide-1 regulates mitochondrial biogenesis and tau phosphorylation against advanced glycation end product-induced neuronal insult: Studies in vivo and in vitro","volume":"300","author":"An","year":"2015","journal-title":"Neuroscience"},{"key":"10.1016\/j.yfrne.2025.101217_b0025","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/24094","article-title":"The genome sequence of Rickettsia prowazekii and the origin of mitochondria","volume":"396","author":"Andersson","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.yfrne.2025.101217_b0030","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1098\/rstb.2002.1193","article-title":"On the origin of mitochondria: a genomics perspective","volume":"358","author":"Andersson","year":"2003","journal-title":"Philos. Trans. R. Soc., B"},{"key":"10.1016\/j.yfrne.2025.101217_b0035","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/1873-3468.12964","article-title":"Role of mitochondrial ROS in the brain: from physiology to neurodegeneration","volume":"592","author":"Angelova","year":"2018","journal-title":"FEBS Lett."},{"key":"10.1016\/j.yfrne.2025.101217_b0040","article-title":"Molecular basis of Leigh syndrome: a current look","volume":"15","author":"Baldo","year":"2020","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.yfrne.2025.101217_b0045","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/S0140-6736(21)00218-X","article-title":"Parkinson\u2019s disease","volume":"397","author":"Bloem","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.yfrne.2025.101217_b0050","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3233\/JPD-201981","article-title":"Mitochondria and Parkinson\u2019s Disease: Clinical, molecular, and translational aspects","volume":"11","author":"Borsche","year":"2020","journal-title":"Journal of Parkinson S Disease"},{"key":"10.1016\/j.yfrne.2025.101217_b0055","doi-asserted-by":"crossref","first-page":"789","DOI":"10.3390\/molecules25245789","article-title":"Comprehensive review on Alzheimer\u2019s disease: Causes and treatment","volume":"25","author":"Breijyeh","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.yfrne.2025.101217_b0060","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1007\/s11064-010-0307-z","article-title":"Cellular stress responses, mitostress and carnitine insufficiencies as critical determinants in aging and neurodegenerative disorders: role of Hormesis and Vitagenes","volume":"35","author":"Calabrese","year":"2010","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.yfrne.2025.101217_b0065","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1099\/00207713-52-2-297","article-title":"The phagotrophic origin of eukaryotes and phylogenetic classification of Protozoa","volume":"52","author":"Cavalier-Smith","year":"2002","journal-title":"Int. J. Syst. Evol. Microbiol."},{"key":"10.1016\/j.yfrne.2025.101217_b0070","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s10522-023-10050-1","article-title":"Aging, oxidative stress and degenerative diseases: mechanisms, complications and emerging therapeutic strategies","volume":"24","author":"Chaudhary","year":"2023","journal-title":"Biogerontology"},{"issue":"1","key":"10.1016\/j.yfrne.2025.101217_b0075","doi-asserted-by":"crossref","first-page":"e541","DOI":"10.1097\/AS9.0000000000000541","article-title":"Bariatric surgery is associated with reduced incidence of mild cognitive impairment and Alzheimer Disease and related dementias: a retrospective cohort study","volume":"6","author":"Chen","year":"2025","journal-title":"Annals of Surgery Open"},{"key":"10.1016\/j.yfrne.2025.101217_b0080","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/S1474-4422(17)30401-5","article-title":"Novel genes associated with amyotrophic lateral sclerosis: diagnostic and clinical implications","volume":"17","author":"Chia","year":"2017","journal-title":"The Lancet Neurology"},{"key":"10.1016\/j.yfrne.2025.101217_b0085","doi-asserted-by":"crossref","DOI":"10.1002\/oby.24274","article-title":"Semaglutide\u2010induced weight loss improves mitochondrial energy efficiency in skeletal muscle","author":"Choi","year":"2025","journal-title":"Obesity"},{"key":"10.1016\/j.yfrne.2025.101217_b0090","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1007\/s12035-020-01926-1","article-title":"The Role of mitochondria in neurodegenerative diseases: the lesson from Alzheimer\u2019s Disease and Parkinson\u2019s Disease","volume":"57","author":"Compagnoni","year":"2020","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.yfrne.2025.101217_b0095","first-page":"38","article-title":"Evoke and Evoke+: Design of two large-scale, double-blind, randomized, placebo-controlled, phase 3 clinical trials of oral semaglutide in early Alzheimer\u2019s disease","volume":"17","author":"Cummings","year":"2025","journal-title":"Alzheimer\u2019s Research & Therapy"},{"key":"10.1016\/j.yfrne.2025.101217_b0100","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab."},{"key":"10.1016\/j.yfrne.2025.101217_b0105","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a028035","article-title":"Pathology of neurodegenerative diseases","volume":"9","author":"Dugger","year":"2017","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.yfrne.2025.101217_b0110","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1038\/d41586-025-01104-0","article-title":"Do infections have a role in Alzheimer\u2019s disease?","volume":"640","author":"Eisenstein","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.yfrne.2025.101217_b0115","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s00702-020-02167-1","article-title":"Parkinson\u2019s disease treatment: past, present, and future","volume":"127","author":"Elsworth","year":"2020","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.yfrne.2025.101217_b0120","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13098-024-01528-0","article-title":"Semaglutide restores astrocyte\u2013vascular interactions and blood\u2013brain barrier integrity in a model of diet-induced metabolic syndrome","volume":"17","author":"Estato","year":"2025","journal-title":"Diabetol. Metab. Syndr."},{"key":"10.1016\/j.yfrne.2025.101217_b0125","doi-asserted-by":"crossref","first-page":"14499","DOI":"10.3390\/ijms241914499","article-title":"Anti-Amyloid therapies for Alzheimer\u2019s Disease and the Amyloid cascade hypothesis","volume":"24","author":"Fedele","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.yfrne.2025.101217_b0130","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1080\/14656566.2019.1609941","article-title":"Pharmacotherapeutic management of epilepsy in MERRF syndrome","volume":"20","author":"Finsterer","year":"2019","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.yfrne.2025.101217_b0135","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2016.80","article-title":"Mitochondrial diseases","volume":"2","author":"Gorman","year":"2016","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.yfrne.2025.101217_b0140","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/S1474-4422(21)00465-8","article-title":"Recent advances in the diagnosis and prognosis of amyotrophic lateral sclerosis","volume":"21","author":"Goutman","year":"2022","journal-title":"The Lancet Neurology"},{"key":"10.1016\/j.yfrne.2025.101217_b0145","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a011403","article-title":"Mitochondrial evolution","volume":"4","author":"Gray","year":"2012","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"12","key":"10.1016\/j.yfrne.2025.101217_b0150","article-title":"Meeting metformin again for the first time","volume":"10","author":"Green","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.yfrne.2025.101217_b0155","article-title":"Amyotrophic lateral sclerosis","volume":"3","author":"Hardiman","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.yfrne.2025.101217_b0160","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.3390\/ijms25073892","article-title":"Alzheimer\u2019s amyloid hypothesis and antibody therapy: Melting glaciers?","volume":"25","author":"H\u00f8ilund-Carlsen","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.yfrne.2025.101217_b0165","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s007020050067","article-title":"Is sporadic Alzheimer disease the brain type of non-insulin dependent diabetes mellitus? a challenging hypothesis","volume":"105","author":"Hoyer","year":"1998","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.yfrne.2025.101217_b0170","doi-asserted-by":"crossref","first-page":"11520","DOI":"10.3390\/ijms222111520","article-title":"Disentangling mitochondria in Alzheimer\u2019s disease","volume":"22","author":"Johri","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.yfrne.2025.101217_b0175","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.4103\/1673-5374.360289","article-title":"Mitochondria in Huntington\u2019s disease: implications in pathogenesis and mitochondrial-targeted therapeutic strategies","volume":"18","author":"Jurcau","year":"2022","journal-title":"Neural Regen. Res."},{"key":"10.1016\/j.yfrne.2025.101217_b0180","doi-asserted-by":"crossref","first-page":"8363","DOI":"10.3390\/ijms22168363","article-title":"New avenues for the treatment of Huntington\u2019s disease","volume":"22","author":"Kim","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.yfrne.2025.101217_b0185","unstructured":"Kommu, S., Whitfield, P. Semaglutide. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, 2025 Jan. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK603723\/."},{"key":"10.1016\/j.yfrne.2025.101217_b0190","article-title":"Glucagon-like peptide-1 receptor agonists and neurodegeneration","volume":"217","author":"Kopp","year":"2022","journal-title":"Prog. Neurobiol."},{"issue":"4","key":"10.1016\/j.yfrne.2025.101217_b0195","doi-asserted-by":"crossref","first-page":"486","DOI":"10.3390\/ph18040486","article-title":"Overview of metformin and neurodegeneration: a comprehensive review","volume":"18","author":"Kruckzkowska","year":"2025","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.yfrne.2025.101217_b0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2024.103129","article-title":"Semaglutide attenuates doxorubicin-induced cardiotoxicity by ameliorating BNIP3-Mediated mitochondrial dysfunction","volume":"72","author":"Li","year":"2024","journal-title":"Redox Biol."},{"issue":"4","key":"10.1016\/j.yfrne.2025.101217_b0205","article-title":"Tirzepatide alleviates obesity via metabolic and mitochondrial pathway remodeling","volume":"29","author":"Li","year":"2025","journal-title":"iScience"},{"issue":"1","key":"10.1016\/j.yfrne.2025.101217_b0210","doi-asserted-by":"crossref","first-page":"777","DOI":"10.3233\/ADR-230181","article-title":"Clinical evidence for GLP-1 receptor agonists in Alzheimer\u2019s disease","volume":"8","author":"Liang","year":"2024","journal-title":"Journal of Alzheimer's Disease Reports"},{"key":"10.1016\/j.yfrne.2025.101217_b0215","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/ana.26260","article-title":"Natural history of Leigh Syndrome: a study of disease Burden and progression","volume":"91","author":"Lim","year":"2021","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.yfrne.2025.101217_b0220","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2021.697440","article-title":"Glucagon-like peptide-1 receptor agonist ameliorates 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) neurotoxicity through enhancing mitophagy flux and reducing \u0391-synuclein and oxidative stress","volume":"14","author":"Lin","year":"2021","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.yfrne.2025.101217_b0225","article-title":"Semaglutide protects against 6-OHDA toxicity by enhancing autophagy and reducing oxidative stress","volume":"2022","author":"Liu","year":"2022","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.yfrne.2025.101217_b0230","article-title":"History and progress of hypotheses and clinical trials for Alzheimer\u2019s disease","volume":"4","author":"Liu","year":"2019","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.yfrne.2025.101217_b0235","doi-asserted-by":"crossref","first-page":"20704","DOI":"10.3390\/ijms160920704","article-title":"Mitochondria: a therapeutic target for Parkinson\u2019s disease?","volume":"16","author":"Luo","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.yfrne.2025.101217_b0240","article-title":"Semaglutide ameliorates cardiac remodeling in male mice by optimizing energy substrate utilization through the Creb5\/NR4a1 axis","volume":"15","author":"Ma","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.yfrne.2025.101217_b0245","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1042\/BST20170501","article-title":"Mitochondrial abnormalities in Parkinson\u2019s disease and Alzheimer\u2019s disease: can mitochondria be targeted therapeutically?","volume":"46","author":"Macdonald","year":"2018","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.yfrne.2025.101217_b0250","doi-asserted-by":"crossref","first-page":"733","DOI":"10.3390\/biomedicines13030733","article-title":"Leigh Syndrome: a Comprehensive review of the disease and present and future treatments","volume":"13","author":"Magro","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.yfrne.2025.101217_b0255","article-title":"Therapeutic potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity","volume":"1233\u20131248","author":"Mahapatra","year":"2022","journal-title":"Non-Alc"},{"issue":"3","key":"10.1016\/j.yfrne.2025.101217_b0260","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s11154-021-09699-1","article-title":"Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes","volume":"23","author":"Mahapatra","year":"2022","journal-title":"Reviews in Endocrine and Metabolic Disorders"},{"issue":"6","key":"10.1016\/j.yfrne.2025.101217_b0265","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1007\/s11095-022-03302-1","article-title":"Therapeutic potential of semaglutide, a newer GLP-1 receptor agonist, in abating obesity, non-alcoholic steatohepatitis and neurodegenerative diseases: a narrative review","volume":"39","author":"Mahapatra","year":"2022","journal-title":"Pharm. Res."},{"key":"10.1016\/j.yfrne.2025.101217_b0270","series-title":"Origin of eukaryotic cells","author":"Margulis","year":"1970"},{"key":"10.1016\/j.yfrne.2025.101217_b0275","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/32096","article-title":"The hydrogen hypothesis for the first eukaryote","volume":"392","author":"Martin","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.yfrne.2025.101217_b0280","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2015.56","article-title":"Alzheimer\u2019s disease","volume":"1","author":"Masters","year":"2015","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.yfrne.2025.101217_b0285","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1056\/NEJMoa2312323","article-title":"Trial of lixisenatide in early Parkinson\u2019s disease","volume":"390","author":"Meissner","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.yfrne.2025.101217_b0290","first-page":"512","article-title":"The effects of GLP-1 receptor agonists on mitochondrial function within skeletal muscle: a systematic review","volume":"16","author":"Old","year":"2025","journal-title":"J. Cachexia. Sarcopenia Muscle"},{"key":"10.1016\/j.yfrne.2025.101217_b0295","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1146\/annurev.genom.6.080604.162249","article-title":"Mitochondrial DNA and Human Evolution","volume":"6","author":"Pakendorf","year":"2005","journal-title":"Annu. Rev. Genomics Hum. Genet."},{"key":"10.1016\/j.yfrne.2025.101217_b0300","doi-asserted-by":"crossref","first-page":"13954","DOI":"10.3390\/ijms232213954","article-title":"Alzheimer\u2019s Disease: treatment strategies and their limitations","volume":"23","author":"Passeri","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.yfrne.2025.101217_b0305","doi-asserted-by":"crossref","first-page":"12486","DOI":"10.3390\/ijms241512486","article-title":"Exploring molecular targets for mitochondrial therapies in neurodegenerative diseases","volume":"24","author":"Plascencia-Villa","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.yfrne.2025.101217_b0310","doi-asserted-by":"crossref","DOI":"10.26502\/aimr.0189","article-title":"Semaglutide: Double-edged Sword with risks and Benefits","volume":"8","author":"Pillarisetti","year":"2025","journal-title":"Archives of Internal Medicine Research"},{"key":"10.1016\/j.yfrne.2025.101217_b0315","doi-asserted-by":"crossref","first-page":"17013","DOI":"10.1038\/nrdp.2017.13","article-title":"Parkinson disease","volume":"3","author":"Poewe","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"5","key":"10.1016\/j.yfrne.2025.101217_b0320","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/cvr\/cvae047","article-title":"SGLT2 inhibitors: from glucose-lowering to cardiovascular protection","volume":"120","author":"Preda","year":"2024","journal-title":"Cardiovasc. Res."},{"issue":"7","key":"10.1016\/j.yfrne.2025.101217_b0325","article-title":"Metformin targets mitochondrial complex I to lower blood glucose","volume":"10","author":"Reczek","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.yfrne.2025.101217_b0330","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2022.970925","article-title":"The neuroprotective effects of GLP-1 in Alzheimer\u2019s and Parkinson\u2019s disease: an in-depth review","volume":"16","author":"Reich","year":"2022","journal-title":"Front. Neurosci."},{"issue":"4","key":"10.1016\/j.yfrne.2025.101217_b0335","article-title":"Brain-uptake pharmacokinetics of albiglutide, dulaglutide, and related GLP-1 analogs","volume":"12","author":"Rhea","year":"2024","journal-title":"Tissue Barriers"},{"key":"10.1016\/j.yfrne.2025.101217_b0340","doi-asserted-by":"crossref","first-page":"9966","DOI":"10.3390\/ijms25189966","article-title":"Understanding amyotrophic lateral sclerosis: Pathophysiology, diagnosis, and therapeutic advances","volume":"25","author":"Rizea","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.yfrne.2025.101217_b0345","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S1474-4422(10)70245-3","article-title":"Huntington\u2019s disease: from molecular pathogenesis to clinical treatment","volume":"10","author":"Ross","year":"2010","journal-title":"The Lancet Neurology"},{"key":"10.1016\/j.yfrne.2025.101217_b0350","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2018.00672","article-title":"Pleiotropic effects of GLP-1 and analogs on cell signaling, metabolism, and function","volume":"9","author":"Rowlands","year":"2018","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.yfrne.2025.101217_b0355","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1056\/NEJMra0909142","article-title":"Alzheimer\u2019s Disease","volume":"362","author":"Querfurth","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.yfrne.2025.101217_b0360","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","article-title":"Alzheimer\u2019s disease","volume":"397","author":"Scheltens","year":"2021","journal-title":"Lancet"},{"issue":"7 supplement 1","key":"10.1016\/j.yfrne.2025.101217_b0365","article-title":"Baseline Characteristics from Evoke and Evoke+: two phase 3 Randomized Placebo-controlled Trials of Oral Semaglutide in patients with Early Alzheimer\u2019s Disease (P11-9.013)","volume":"102","author":"Scheltens","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.yfrne.2025.101217_b0370","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1038\/s41591-023-02505-2","article-title":"Emerging diagnostics and therapeutics for Alzheimer disease","volume":"29","author":"Self","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.yfrne.2025.101217_b0375","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.3390\/molecules24081583","article-title":"Oxidative stress: a key modulator in neurodegenerative diseases","volume":"24","author":"Singh","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.yfrne.2025.101217_b0380","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jconrel.2024.01.047","article-title":"Alzheimer\u2019s disease current therapies, novel drug delivery systems and future directions for better disease management","volume":"367","author":"Singh","year":"2024","journal-title":"J. Control. Release"},{"key":"10.1016\/j.yfrne.2025.101217_b0385","article-title":"The role of mitochondria in amyotrophic lateral sclerosis","volume":"710","author":"Smith","year":"2017","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.yfrne.2025.101217_b0390","article-title":"Safety of semaglutide","volume":"12","author":"Smits","year":"2021","journal-title":"Front. Endocrinol."},{"issue":"6","key":"10.1016\/j.yfrne.2025.101217_b0395","article-title":"Mitochondria: a Covert Chronic Infection Masquerading as a Symbiotic Partner?","volume":"30","author":"Stefano","year":"2025","journal-title":"FBL"},{"issue":"2","key":"10.1016\/j.yfrne.2025.101217_b0400","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3390\/v17020146","article-title":"Primordial Biochemicals within Coacervate-like Droplets and the Origins of Life","volume":"17","author":"Stefano","year":"2025","journal-title":"Viruses"},{"key":"10.1016\/j.yfrne.2025.101217_b0405","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2023.1130197","article-title":"Independent and sensory human mitochondrial functions reflecting symbiotic evolution","author":"Stefano","year":"2023","journal-title":"Front. Cell. Infect. Microbiol."},{"issue":"1","key":"10.1016\/j.yfrne.2025.101217_b0410","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s10571-024-01503-3","article-title":"Viruses and Mitochondrial Dysfunction in Neurodegeneration and Cognition: an Evolutionary Perspective","volume":"44","author":"Stefano","year":"2024","journal-title":"Cell. Mol. Neurobiol."},{"key":"10.1016\/j.yfrne.2025.101217_b0415","doi-asserted-by":"crossref","DOI":"10.61936\/themind\/202412123","article-title":"Semaglutide: a potential therapeutic for Mitochondria-Associated disorders","volume":"3","author":"Stefano","year":"2024","journal-title":"The MIND - Bulletin on Mind-Body Medicine Research"},{"key":"10.1016\/j.yfrne.2025.101217_b0420","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1136\/practneurol-2021-003074","article-title":"Huntington\u2019s disease: diagnosis and management","volume":"22","author":"Stoker","year":"2021","journal-title":"Pract. Neurol."},{"key":"10.1016\/j.yfrne.2025.101217_b0425","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.pneurobio.2013.04.004","article-title":"Mitochondrial dysfunction and oxidative stress in Parkinson\u2019s disease","volume":"106\u2013107","author":"Subramaniam","year":"2013","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.yfrne.2025.101217_b0430","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.3233\/JAD-170585","article-title":"Mitochondria and mitochondrial cascades in Alzheimer\u2019s disease","volume":"62","author":"Swerdlow","year":"2017","journal-title":"Journal of Alzheimer S Disease"},{"key":"10.1016\/j.yfrne.2025.101217_b0435","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.mehy.2003.12.045","article-title":"A \u201cmitochondrial cascade hypothesis\u201d for sporadic Alzheimer\u2019s disease","volume":"63","author":"Swerdlow","year":"2004","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.yfrne.2025.101217_b0440","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.expneurol.2009.01.011","article-title":"The Alzheimer\u2019s disease mitochondrial cascade hypothesis: an update","volume":"218","author":"Swerdlow","year":"2009","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.yfrne.2025.101217_b0445","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1007\/s11011-021-00772-x","article-title":"Clinical features, pathogenesis, and management of stroke-like episodes due to MELAS","volume":"36","author":"Tetsuka","year":"2021","journal-title":"Metab. Brain Dis."},{"issue":"1","key":"10.1016\/j.yfrne.2025.101217_b0450","article-title":"GLP-1\/GIP dual agonist tirzepatide alleviates Parkinson\u2019s disease model by promoting mitochondrial homeostasis","volume":"67","author":"Tian","year":"2025","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"9","key":"10.1016\/j.yfrne.2025.101217_b0455","doi-asserted-by":"crossref","first-page":"4972","DOI":"10.3390\/ijms25094972","article-title":"A systematic review of semaglutide\u2019s influence on cognition and neurological outcomes","volume":"25","author":"Tipa","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.yfrne.2025.101217_b0460","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S1474-4422(21)00030-2","article-title":"Challenges in the diagnosis of Parkinson\u2019s disease","volume":"20","author":"Tolosa","year":"2021","journal-title":"The Lancet Neurology"},{"key":"10.1016\/j.yfrne.2025.101217_b0465","article-title":"Mitochondrial disorder: Kearns-Sayre Syndrome","volume":"161\u2013162","author":"Tsang","year":"2018","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.yfrne.2025.101217_b0470","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1007\/s11064-023-03904-0","article-title":"Mitochondrial Dysfunction and Parkinson\u2019s Disease: Pathogenesis and therapeutic strategies","volume":"48","author":"Vastegani","year":"2023","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.yfrne.2025.101217_b0475","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(24)02808-3","article-title":"Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial","volume":"405","author":"Vijiaratnam","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.yfrne.2025.101217_b0480","doi-asserted-by":"crossref","DOI":"10.1186\/s13024-020-00376-6","article-title":"Mitochondria dysfunction in the pathogenesis of Alzheimer\u2019s disease: recent advances","volume":"15","author":"Wang","year":"2020","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.yfrne.2025.101217_b0485","article-title":"Associations of semaglutide with first\u2010time diagnosis of Alzheimer\u2019s disease in patients with type 2 diabetes: Target trial emulation using nationwide real\u2010world data in the US","author":"Wang","year":"2024","journal-title":"Alzheimer S & Dementia"},{"key":"10.1016\/j.yfrne.2025.101217_b0490","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116496","article-title":"Current Therapy in Amyotrophic lateral sclerosis (ALS): a review on past and Future Therapeutic strategies","volume":"272","author":"Wei","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.yfrne.2025.101217_b0495","author":"World Health","year":"2017","journal-title":"Organization"},{"key":"10.1016\/j.yfrne.2025.101217_b0500","unstructured":"World Health Organization (2023); available at https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/parkinson-disease."},{"key":"10.1016\/j.yfrne.2025.101217_b0505","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114578","article-title":"GLP-1 improves the neuronal supportive ability of astrocytes in Alzheimer\u2019s disease by regulating mitochondrial dysfunction via the cAMP\/PKA pathway","volume":"188","author":"Xie","year":"2021","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.yfrne.2025.101217_b0510","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3390\/cells8040379","article-title":"Mitochondrial DNA: distribution, mutations, and elimination","volume":"8","author":"Yan","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.yfrne.2025.101217_b0515","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1146\/annurev-pathmechdis-031521-034145","article-title":"Genetics and pathogenesis of Parkinson\u2019s Syndrome","volume":"18","author":"Ye","year":"2022","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.yfrne.2025.101217_b0520","article-title":"Impact of SGLT2 inhibitors on NAFLD\/NASH: Mitochondrial function and autophagy","volume":"16","author":"Yoo","year":"2025","journal-title":"Front. Endocrinol."},{"issue":"1","key":"10.1016\/j.yfrne.2025.101217_b0525","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct. Target. Ther."}],"container-title":["Frontiers in Neuroendocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091302225000433?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091302225000433?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T06:21:19Z","timestamp":1763533279000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091302225000433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":105,"alternative-id":["S0091302225000433"],"URL":"https:\/\/doi.org\/10.1016\/j.yfrne.2025.101217","relation":{},"ISSN":["0091-3022"],"issn-type":[{"value":"0091-3022","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Semaglutide and the pathogenesis of progressive neurodegenerative disease: the central role of mitochondria","name":"articletitle","label":"Article Title"},{"value":"Frontiers in Neuroendocrinology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yfrne.2025.101217","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101217"}}